Comparative Pharmacology
Head-to-head clinical analysis: BENYLIN versus LARGON.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENYLIN versus LARGON.
BENYLIN vs LARGON
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BENYLIN (diphenhydramine) is a first-generation antihistamine that competitively antagonizes histamine at H1 receptors, thereby alleviating allergic symptoms. It also crosses the blood-brain barrier and acts as a central nervous system depressant via inhibition of histamine and acetylcholine, producing sedative, antiemetic, and antitussive effects.
Propionazine is a phenothiazine derivative that acts as a central dopamine receptor antagonist, particularly at D2 receptors. It also exhibits antihistaminergic, anticholinergic, and sedative effects by blocking histamine H1 and muscarinic receptors.
Oral: 10-20 mL (25-50 mg diphenhydramine) every 4-6 hours; maximum 100 mg per day.
50 mg intramuscularly every 4-6 hours as needed for nausea and vomiting. Maximum: 300 mg/day.
None Documented
None Documented
Terminal elimination half-life: 4-6 hours in adults; extended to 10-12 hours in hepatic impairment, increasing risk of accumulation.
Terminal elimination half-life is 20-30 hours in healthy adults, extending up to 40-60 hours in patients with hepatic impairment or elderly.
Renal: ~80% as unchanged drug and glucuronide conjugates; fecal/biliary: ~20%.
Primarily renal (approximately 50-80% as unchanged drug and metabolites) via glomerular filtration and tubular secretion; minor biliary/fecal elimination (~10-15%).
Category C
Category C
Antihistamine
Antihistamine